热门资讯> 正文
Scinai股价在银屑病药物临床前研究中飙升54%
2024-07-15 23:08
- Scinai Immunotherapeutics (NASDAQ:SCNI) stock soared 54% in Monday morning trading after the Israeli biotech reported positive results from a pre-clinical study of its NanoAb therapy candidate in the treatment of plaque psoriasis.
- The study showed inflammatory markers in modified mice treated with the NanoAb product were similar to those of two comparator drugs. As opposed to other therapies used to treat the condition, NanoAb, anti IL-17A/F VHH antibody fragment, is administered directly into skin lesions via a short needle, according to a statement.
- Scinai intends to conduct a follow-on in vivo animal study in late 2024, with a first-in-human clinical trial expected to begin in late 2025.
More on Scinai Immunotherapeutics
- Financial information for Scinai Immunotherapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
